Bladder wall fibrosis following intravesical mitomycin treatment for superficial bladder cancer.
Mitomycin is used extensively for the prevention of recurrence of superficial bladder cancer. Most treatment regimens of mitomycin are long term, since this seems more effective in preventing recurrence. During treatment some patients develop cystitis of variable severity, which may lead to mucosal ulcerations and cessation of treatment. We report a case in which long-term treatment with mitomycin, following a single episode of transitional cell bladder cancer, has led to bladder fibrosis and loss of its function, without evidence of tumor recurrence.
Katz
G
G
Department of Pathology, University of Florida, Gainesville, USA.
Hackett
R L
RL
Wajsman
Z
Z
D000283:Administration, Intravesical; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D005355:Fibrosis; D006801:Humans; D008297:Male; D008937:Mitomycins / Q000008:administration & dosage / Q000009:adverse effects*; D001743:Urinary Bladder / Q000473:pathology*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D008937:Mitomycins